Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cardiff Oncology, Inc. is a biotechnology company focused on developing targeted cancer therapies, primarily through PLK1 inhibition. Its lead candidate, onvansertib, is an oral, highly selective PLK1 inhibitor used in combination with standard chemotherapies for various cancers, including metastatic colorectal, pancreatic, lung, and breast cancers. The company leverages biomarker-driven clinical trials and strategic partnerships to address unmet medical needs in oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.